Bruker Corporation (NASDAQ:BRKR) – Investment analysts at Jefferies Group lifted their Q3 2018 EPS estimates for Bruker Corporation in a research note issued on Thursday. Jefferies Group analyst B. Couillard now expects that the medical research company will post earnings of $0.33 per share for the quarter, up from their previous forecast of $0.32. Jefferies Group also issued estimates for Bruker Corporation’s Q4 2018 earnings at $0.40 EPS, FY2018 earnings at $1.35 EPS and FY2019 earnings at $1.52 EPS.

Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Bruker Corporation had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. During the same quarter in the previous year, the firm posted $0.32 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/q3-2018-earnings-estimate-for-bruker-corporation-issued-by-jefferies-group-brkr/1699602.html.

A number of other research analysts have also issued reports on BRKR. BidaskClub lowered Bruker Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Bank of America Corporation upgraded Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target for the company in a research report on Friday, November 3rd. Zacks Investment Research upgraded Bruker Corporation from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research report on Wednesday, November 8th. Cowen and Company reiterated a “hold” rating and set a $29.00 price target on shares of Bruker Corporation in a research report on Friday, November 3rd. Finally, J P Morgan Chase & Co upgraded Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price target for the company in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $29.64.

Bruker Corporation (NASDAQ BRKR) opened at $31.83 on Monday. Bruker Corporation has a 12-month low of $21.03 and a 12-month high of $35.16. The stock has a market capitalization of $4,951.56, a P/E ratio of 27.20, a P/E/G ratio of 2.69 and a beta of 1.05. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60.

A number of hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. increased its position in Bruker Corporation by 4.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 579,549 shares of the medical research company’s stock worth $17,242,000 after purchasing an additional 24,524 shares during the last quarter. Wells Fargo & Company MN increased its position in Bruker Corporation by 4.7% in the 3rd quarter. Wells Fargo & Company MN now owns 845,373 shares of the medical research company’s stock worth $25,150,000 after purchasing an additional 37,858 shares during the last quarter. Citadel Advisors LLC increased its position in Bruker Corporation by 107.4% in the 3rd quarter. Citadel Advisors LLC now owns 266,256 shares of the medical research company’s stock worth $7,921,000 after purchasing an additional 137,879 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Bruker Corporation by 16.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 282,808 shares of the medical research company’s stock worth $8,376,000 after acquiring an additional 39,519 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Bruker Corporation by 10.2% during the 3rd quarter. Legal & General Group Plc now owns 42,588 shares of the medical research company’s stock worth $1,267,000 after acquiring an additional 3,942 shares in the last quarter. 65.47% of the stock is currently owned by institutional investors.

In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 35.20% of the company’s stock.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Earnings History and Estimates for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.